
Risk of secondary cancers after CAR-T cell therapy just 6.5%
A large study has found that the risk of secondary blood cancers after CAR-T cell therapy is low, despite the Food and Drug Administration (FDA) warning. In November 2023, the FDA issued a warning about a risk of secondary cancers that may be associated with… Read More
